| scholarly article | Q13442814 |
| P2093 | author name string | Bin Zhao | |
| Kun-Liang Guan | |||
| Zhi-Chun Lai | |||
| Xin Ye | |||
| Joungmok Kim | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1089-98 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein | |
| P478 | volume | 69 |
| Q46115640 | A Novel YAP1 Inhibitor targets CSCs-enriched Radiation Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. |
| Q26782842 | A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas |
| Q42154602 | A TEAD1/p65 complex regulates the eutherian-conserved MnSOD intronic enhancer, eRNA transcription and the innate immune response |
| Q36438072 | A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness |
| Q24293710 | A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP) |
| Q64914877 | A novel YAP1/SLC35B4 regulatory axis contributes to proliferation and progression of gastric carcinoma. |
| Q36413318 | ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer |
| Q37219985 | ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence. |
| Q37410567 | Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression |
| Q24323326 | Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein |
| Q60044115 | Arenobufagin induces MCF-7 cell apoptosis by promoting JNK-mediated multisite phosphorylation of Yes-associated protein |
| Q34168500 | Control of tissue growth and cell transformation by the Salvador/Warts/Hippo pathway |
| Q36304149 | Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade |
| Q28586255 | Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse |
| Q49797899 | DNA binding partners of YAP/TAZ. |
| Q35100037 | Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response |
| Q30275987 | Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis |
| Q28086905 | Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer |
| Q24293337 | Evolutionary and molecular facts link the WWC protein family to Hippo signaling |
| Q43375954 | Expression of MicroRNA-29a Regulated by Yes-Associated Protein Modulates the Neurite Outgrowth in N2a Cells. |
| Q46209871 | Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors |
| Q38872721 | Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor. |
| Q38779591 | Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis. |
| Q24614424 | Hippo pathway-independent restriction of TAZ and YAP by angiomotin |
| Q38838116 | Hippo signaling in the kidney: the good and the bad. |
| Q36091095 | Hippo signaling is required for Notch-dependent smooth muscle differentiation of neural crest |
| Q38231786 | Hippo-YAP signaling pathway: A new paradigm for cancer therapy |
| Q37923302 | Integrating developmental signals: a Hippo in the (path)way |
| Q33654331 | Molecular evolution of the Yap/Yorkie proto-oncogene and elucidation of its core transcriptional program |
| Q36434018 | Myocardin-Related Transcription Factor A and Yes-Associated Protein Exert Dual Control in G Protein-Coupled Receptor- and RhoA-Mediated Transcriptional Regulation and Cell Proliferation |
| Q36738876 | Negative correlation of ITCH E3 ubiquitin ligase and miRNA-106b dictates metastatic progression in pancreatic cancer |
| Q36932907 | Neogenin Promotes BMP2 Activation of YAP and Smad1 and Enhances Astrocytic Differentiation in Developing Mouse Neocortex. |
| Q37479128 | Notch3 inhibits epithelial-mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells |
| Q62661552 | Overexpression of YAP1 induces immortalization of normal human keratinocytes by blocking clonal evolution |
| Q36647912 | PML Surfs into HIPPO Tumor Suppressor Pathway. |
| Q52579777 | PRDM4 mediates YAP-induced cell invasion by activating leukocyte-specific integrin β2 expression. |
| Q42625092 | Phosphorylation-independent repression of Yorkie in Fat-Hippo signaling. |
| Q34062012 | Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas |
| Q55510312 | Quantitative Analysis Reveals that Actin and Src-Family Kinases Regulate Nuclear YAP1 and Its Export. |
| Q37720402 | RUNX3 is multifunctional in carcinogenesis of multiple solid tumors |
| Q47100063 | Regulation of Tissue Growth by the Mammalian Hippo Signaling Pathway. |
| Q58739088 | Repurposing of Drugs Targeting YAP-TEAD Functions |
| Q39005862 | Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways |
| Q35688452 | Ski regulates Hippo and TAZ signaling to suppress breast cancer progression |
| Q37825816 | Snapshots of a hybrid transcription factor in the Hippo pathway |
| Q37524477 | Splice variant insertions in the C-terminus impairs YAP's transactivation domain. |
| Q27659386 | Structural insights into the YAP and TEAD complex |
| Q24612471 | Structures of YAP protein domains reveal promising targets for development of new cancer drugs |
| Q39867711 | TEADs mediate nuclear retention of TAZ to promote oncogenic transformation |
| Q35826016 | TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth |
| Q90350507 | Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma |
| Q28078129 | Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy |
| Q37875188 | The Hippo pathway and apico-basal cell polarity |
| Q37800053 | The Hippo pathway in biological control and cancer development |
| Q33937666 | The Hippo pathway in disease and therapy: cancer and beyond |
| Q90966566 | The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration |
| Q38940749 | The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes |
| Q36236290 | The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain |
| Q30395225 | The Hippo signaling pathway and translational opportunities for brain cancers |
| Q28281214 | The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version |
| Q47316032 | The emerging role of Hippo signaling pathway in regulating osteoclast formation. |
| Q33654365 | The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis |
| Q38757064 | The hippo signaling pathway: implications for heart regeneration and disease |
| Q36331217 | The induction of yes-associated protein expression after arterial injury is crucial for smooth muscle phenotypic modulation and neointima formation |
| Q38255378 | The mammalian Hippo pathway: regulation and function of YAP1 and TAZ. |
| Q44860085 | The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in Southern and Eastern Chinese populations |
| Q38943407 | The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner. |
| Q42378384 | The prognostic impacts of TEA domain (TEAD) transcription factor polymorphisms in Chinese hepatocellular carcinoma patients |
| Q28507317 | The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation |
| Q34786592 | The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway |
| Q42927483 | Transcription and processing: multilayer controls of RNA biogenesis by the Hippo pathway |
| Q40122705 | Two distinct roles of the yorkie/yap gene during homeostasis in the planarian Dugesia japonica |
| Q94527337 | Verteporfin induced SUMOylation of YAP1 in endometrial cancer |
| Q37890248 | WW domain interactions regulate the Hippo tumor suppressor pathway |
| Q24304338 | WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ |
| Q35210623 | Wbp2 cooperates with Yorkie to drive tissue growth downstream of the Salvador-Warts-Hippo pathway |
| Q89055887 | YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity |
| Q36237330 | YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. |
| Q39815073 | Yap1 is dispensable for self-renewal but required for proper differentiation of mouse embryonic stem (ES) cells |
| Q37269206 | Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. |
| Q30394387 | Yes-associated protein 1 is activated and functions as an oncogene in meningiomas |
| Q34077954 | Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis |
| Q36881080 | Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma |
| Q34122782 | Yorkie promotes transcription by recruiting a histone methyltransferase complex |
| Q37746333 | Yorkie: the final destination of Hippo signaling. |
| Q36898504 | cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. |
Search more.